Joshiah Gordon, DO
Pulmonary Disease · Pueblo, CONPI 1952454290
Payments from drug & device makers
Across 435 payments — averaging $520.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$131K
- Actelion Pharmaceuticals US, Inc.$32K
- Grifols USA, LLC$26K
- Insmed, Inc.$15K
- Bayer$9K
- Intuitive Surgical$6K
- plus $6K from 20 others
What the payments were for
- Consulting fees$14,0307%
- Speaking & faculty fees$163,72479%
- Travel & lodging$13,6987%
- Food & beverage$12,1666%
- Education$4,2342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 179 | $131,155 |
| Actelion Pharmaceuticals US, Inc. | 62 | $32,205 |
| Grifols USA, LLC | 62 | $26,218 |
| Insmed, Inc. | 17 | $15,340 |
| Bayer | 12 | $8,881 |
| Intuitive Surgical | 18 | $6,491 |
| Medtronic | 3 | $1,540 |
| Pulmonx Corporation | 13 | $1,078 |
| Mylan Specialty L.p. | 1 | $870 |
| Grifols Shared Services North America, Inc. | 3 | $799 |
| Olympus Corporation Of The Americas | 7 | $510 |
| AstraZeneca | 14 | $270 |
| GSK | 18 | $217 |
| Regeneron Healthcare Solutions, Inc. | 3 | $173 |
| Philips North America LLC | 7 | $128 |
| Sanofi | 5 | $110 |
| Genentech USA, Inc. | 1 | $100 |
| Veran Medical Technologies, Inc. | 2 | $89 |
| Astellas Pharma US Inc | 1 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Boston Scientific | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $18 |
| Sandoz | 1 | $16 |
| Biogen | 1 | $15 |
| Resmed Corp | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENITRAM$48,824
- TYVASO$42,287
- OPSUMIT$31,464
- UPTRAVI$31,339
- REMODULIN$30,294
- Prolastin-C Liquid$21,569
- NONE$14,552
- Arikayce$13,483
- Adempas$8,721
- Da Vinci Surgical System$6,226
- Prolastin-C$4,260
- ILLUMISITE$1,540
- Yupelri$870
- CHARTIS CATHETER$796
- ZEPHYR DELIVERY CATHETER$796
- ZEPHYR ENDOBRONCHIAL VALVE$796
- PULMONX CHARTIS TABLET CONSOLE$796
- Olympus Bronchoscopes$405
- Olympus Capital Accessories$405
- Olympus Respiratory Accessories$405
How this compares
$226,342 in reported general payments places this provider in the 90th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 152 | $1,072,391 |
| AdempasRiociguat | 61 | $714,382 |
| OpsumitMacitentan | 52 | $661,305 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 485 | $453,737 |
| Tyvaso DpiTreprostinil | 14 | $330,209 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 25 | $291,931 |
| Spiriva RespimatTiotropium Bromide | 205 | $185,604 |
| OfevNintedanib Esylate | 14 | $177,624 |
| Spiriva HandihalerTiotropium Bromide | 188 | $168,908 |
| Ambrisentan | 82 | $168,770 |
| Breo ElliptaFluticasone/Vilanterol | 137 | $87,888 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 107 | $76,220 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 59 | $63,885 |
| EliquisApixaban | 40 | $44,427 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $42,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $8,881 | $714,38261 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $32,205 | $661,30552 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $217 | $660,652820 claims |
| Grifols USA, LLCProlastin C | $26,218 | $291,93125 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $270 | $106,687166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 248 pulmonary disease providers in Colorado.
Other pulmonary disease in Pueblo
- David SchwartzAurora$6.7M
- Michael WechslerDenver$3.6M
- David BadeschAurora$2.2M
- Jennifer Taylor CousarDenver$1.4M
- Evans Fernandez PerezDenver$1.3M
- Ronald BalkissoonDenver$1.2M
- Jeffrey SwigrisDenver$845K
- Joshua SolomonDenver$705K
- Thomas WilcoxBoulder$698K
- Marjorie GeorgeDenver$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.